Recent Updates
Recently added Catalysts

Postbariatric Hypoglycemia: one US-listed biotech with a clinical-stage programme

Cardiovascular & MetabolicUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$3.8Buniverse median $1.20B
Allocated capital$1.9B$3.8B competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank103/299crowding rank 127

Postbariatric Hypoglycemia is uncontested. Amylyx Pharmaceuticals (AMLX) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Avexitide in phase 3.

There is no public comparable to price it against. AMLX spreads its $3.8B market cap across 2 indications, so $1.9B of it is allocated here.

The one programme here is in late-stage development, with 1 dated catalyst in the next 12 months.

$1.9B of allocated capital sits in Postbariatric Hypoglycemia, ranking it 103rd of 299 indications by the money committed to it.

Companies developing drugs for Postbariatric Hypoglycemia 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
AMLXAmylyx PharmaceuticalsAvexitidePhase 31$3.8BNo2 30 Sep 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Postbariatric Hypoglycemia counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Postbariatric Hypoglycemia has one competitor and a median of $3.8B.

Cardiovascular & Metabolic

Cardiovascular & Metabolic holds $89.7B of the map's capital, 13.4% of the total, spread across 29 indications and 44 companies. 9 of those indications have more than one company competing.

See every Cardiovascular & Metabolic indication on the map

Related indications in Cardiovascular & Metabolic

ATTR Amyloidosis2 companies · $2.0B · median $5.7BConcentrated betCardiovascular1 company · $1.8B · median $5.5BUncontestedHyperlipidemia1 company · $1.7B · median $12.2BUncontestedCholestatic Liver Disease1 company · $2.2B · median $6.5BUncontestedChronic Heart Failure With Reduced Ejection Fraction1 company · $2.3B · median $9.2BUncontestedHeart Failure with Decompensation1 company · $2.3B · median $9.2BUncontestedAtherosclerotic Cardiovascular Disease Management1 company · $1.0B · median $3.1BUncontestedDyslipidemia1 company · $1.0B · median $3.1BUncontested

Postbariatric Hypoglycemia pipeline questions

Which biotech companies are developing drugs for Postbariatric Hypoglycemia?

Amylyx Pharmaceuticals (AMLX, Avexitide, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Postbariatric Hypoglycemia.

How advanced is the Postbariatric Hypoglycemia pipeline?

Of the 1 clinical-stage programme in Postbariatric Hypoglycemia, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Postbariatric Hypoglycemia?

No. AMLX is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Postbariatric Hypoglycemia, which is why the indication is classified as uncontested.

When is the next Postbariatric Hypoglycemia catalyst?

The next dated catalyst in Postbariatric Hypoglycemia is AMLX on 30 Sep 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map